AOD-9604 is only the small C-terminal 176-191 fragment, so it lacks those receptor-binding regions and, in research models, does not reproduce growth hormone's growth-promoting or glucose-affecting actions it is studied specifically for the lipid-metabolism activity mapped to this fragment
(3) AOD 9604 Peptide and Obesity In 2004, clinical trials observed the actions of the peptide in 300 obese subjects who were given the peptide for 12 weeks
See GLP-1 Peptides Explained for broader context on GLP-1 therapy
In this blog, we'll discuss everything you need to know about menorrhagia, its meaning, its symptoms, why it happens, and the effective menorrhagia treatment options
Potential Risks and Side Effects The FDA states that compounded drugs containing AOD-9604 carry a significant risk for immunogenicity